Watchful waiting for elderly patients with localized prostate cancer

Watchful-waiting policy is an important treatment option for some patients with localized prostate cancer and it is widely recognized in Western countries in which the prostate cancer mortality rate is 510 fold higher than that in Japan. Most men with well and perhaps moderately differentiated prost...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 51(2005), 8 vom: 15. Aug., Seite 561-3
1. Verfasser: Maeda, Osamu (VerfasserIn)
Weitere Verfasser: Kakimoto, Ken-ichi, Ono, Yutaka, Meguro, Norio, Kinouchi, Toshiaki, Usami, Michiyuki
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 2005
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:English Abstract Journal Article Prostate-Specific Antigen EC 3.4.21.77
LEADER 01000caa a22002652 4500
001 NLM15778732X
003 DE-627
005 20250206170037.0
007 tu
008 231223s2005 xx ||||| 00| ||jpn c
028 5 2 |a pubmed25n0526.xml 
035 |a (DE-627)NLM15778732X 
035 |a (NLM)16164273 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a jpn 
100 1 |a Maeda, Osamu  |e verfasserin  |4 aut 
245 1 0 |a Watchful waiting for elderly patients with localized prostate cancer 
264 1 |c 2005 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 01.11.2005 
500 |a Date Revised 15.11.2006 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Watchful-waiting policy is an important treatment option for some patients with localized prostate cancer and it is widely recognized in Western countries in which the prostate cancer mortality rate is 510 fold higher than that in Japan. Most men with well and perhaps moderately differentiated prostate cancer who have a life expectancy of less than 10 years will die of other causes and it is not clear whether early primary hormone therapy improves survival and the quality of life compared to androgen suppression deferred until signs and symptoms of clinical progression. There is one major question as to whether patients who do not need radical treatment should undergo early primary hormone therapy in Japan in spite of high cost and treatment-related adverse effects of hormone therapy 
650 4 |a English Abstract 
650 4 |a Journal Article 
650 7 |a Prostate-Specific Antigen  |2 NLM 
650 7 |a EC 3.4.21.77  |2 NLM 
700 1 |a Kakimoto, Ken-ichi  |e verfasserin  |4 aut 
700 1 |a Ono, Yutaka  |e verfasserin  |4 aut 
700 1 |a Meguro, Norio  |e verfasserin  |4 aut 
700 1 |a Kinouchi, Toshiaki  |e verfasserin  |4 aut 
700 1 |a Usami, Michiyuki  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Hinyokika kiyo. Acta urologica Japonica  |d 1962  |g 51(2005), 8 vom: 15. Aug., Seite 561-3  |w (DE-627)NLM012631779  |x 0018-1994  |7 nnns 
773 1 8 |g volume:51  |g year:2005  |g number:8  |g day:15  |g month:08  |g pages:561-3 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_40 
912 |a GBV_ILN_60 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_350 
912 |a GBV_ILN_2001 
912 |a GBV_ILN_2003 
912 |a GBV_ILN_2005 
912 |a GBV_ILN_2006 
912 |a GBV_ILN_2008 
912 |a GBV_ILN_2010 
912 |a GBV_ILN_2012 
912 |a GBV_ILN_2018 
951 |a AR 
952 |d 51  |j 2005  |e 8  |b 15  |c 08  |h 561-3